INTRODUCTION:Allergic rhinitis (AR) impacts around 25% of the worldwide population. However, cost, safety, and a high dissatisfaction rate with numerous conventional medications continues to be an issue in the largest patient surveys, due primarily to a lack of efficacy on nasal congestion. Our previously published randomized trial demonstrated a significant reduction in cold and flu-like symptoms, and a secondary potential observation of a decrease in nasal congestion with an oral yeast-derived compound; therefore, the objective of this study was to test the effects of this same product on nasal congestion and other notable AR symptoms. METHODS: A 12-week, randomized, double-blind, placebo-controlled clinical trial of 96 healthy subjects with a recent clinically documented history of seasonal allergies and AR was conducted. Participants received once-daily supplementation with 500 mg of a dried, modified Saccharomyces cerevisiae oral fermentation product (EpiCor, Embria Health Sciences, Ankeny, Iowa, USA) or placebo during the 12-week period of the highest recorded concentrations of total pollen counts for this Midwest geographic area. Clinical outcome measurements included in-clinic examinations, validated questionnaire and standard diary, and serologic analysis at baseline, 6 and 12 weeks. RESULTS: During the highest pollen count period (weeks 1-6), EpiCor significantly reduced the mean severity of specific AR symptoms, including a significant reduction in nasal congestion (P=0.04), rhinorrhea (P=0.005), and a nonsignificant reduction in ocular discharge symptoms. A significantly (P=0.04) reduced total number of days with nasal congestion (12.5 fewer days) favored EpiCor compared with placebo, as did the nasal congestion section of the quality of life questionnaire (P=0.04). Subjects receiving the intervention also experienced significantly (P=0.03) higher salivary IgA levels. Adverse events were similar to placebo. CONCLUSION: This yeast-derived product appeared to be safe and efficacious, and should receive more clinical research with and without standard medications to reduce the impact of seasonal allergies, especially AR-induced nasal congestion.
RCT Entities:
INTRODUCTION:Allergic rhinitis (AR) impacts around 25% of the worldwide population. However, cost, safety, and a high dissatisfaction rate with numerous conventional medications continues to be an issue in the largest patient surveys, due primarily to a lack of efficacy on nasal congestion. Our previously published randomized trial demonstrated a significant reduction in cold and flu-like symptoms, and a secondary potential observation of a decrease in nasal congestion with an oral yeast-derived compound; therefore, the objective of this study was to test the effects of this same product on nasal congestion and other notable AR symptoms. METHODS: A 12-week, randomized, double-blind, placebo-controlled clinical trial of 96 healthy subjects with a recent clinically documented history of seasonal allergies and AR was conducted. Participants received once-daily supplementation with 500 mg of a dried, modified Saccharomyces cerevisiae oral fermentation product (EpiCor, Embria Health Sciences, Ankeny, Iowa, USA) or placebo during the 12-week period of the highest recorded concentrations of total pollen counts for this Midwest geographic area. Clinical outcome measurements included in-clinic examinations, validated questionnaire and standard diary, and serologic analysis at baseline, 6 and 12 weeks. RESULTS: During the highest pollen count period (weeks 1-6), EpiCor significantly reduced the mean severity of specific AR symptoms, including a significant reduction in nasal congestion (P=0.04), rhinorrhea (P=0.005), and a nonsignificant reduction in ocular discharge symptoms. A significantly (P=0.04) reduced total number of days with nasal congestion (12.5 fewer days) favored EpiCor compared with placebo, as did the nasal congestion section of the quality of life questionnaire (P=0.04). Subjects receiving the intervention also experienced significantly (P=0.03) higher salivary IgA levels. Adverse events were similar to placebo. CONCLUSION: This yeast-derived product appeared to be safe and efficacious, and should receive more clinical research with and without standard medications to reduce the impact of seasonal allergies, especially AR-induced nasal congestion.
Authors: Ching-Yen Lin; Celeste Alexander; Andrew J Steelman; Christine M Warzecha; Maria R C de Godoy; Kelly S Swanson Journal: J Anim Sci Date: 2019-04-03 Impact factor: 3.159
Authors: Gitte S Jensen; Kimberlee A Redman; Kathleen F Benson; Steve G Carter; Marcie A Mitzner; Stuart Reeves; Larry Robinson Journal: J Med Food Date: 2011-04-18 Impact factor: 2.786
Authors: Sofia M Wilson; Patricia M Oba; Samantha A Koziol; Catherine C Applegate; Katiria Soto-Diaz; Andrew J Steelman; Matthew R Panasevich; Sharon A Norton; Kelly S Swanson Journal: J Anim Sci Date: 2022-09-01 Impact factor: 3.338
Authors: Gitte S Jensen; Steve G Carter; Stuart G Reeves; Larry E Robinson; Kathleen F Benson Journal: J Med Food Date: 2014-08-08 Impact factor: 2.786
Authors: M V Pontes; T C M Ribeiro; H Ribeiro; A P de Mattos; I R Almeida; V M Leal; G N Cabral; S Stolz; W Zhuang; D M F Scalabrin Journal: Nutr J Date: 2016-02-27 Impact factor: 3.271
Authors: Iris Pinheiro; Larry Robinson; An Verhelst; Massimo Marzorati; Björn Winkens; Pieter Van den Abbeele; Sam Possemiers Journal: BMC Complement Altern Med Date: 2017-09-04 Impact factor: 3.659
Authors: Massimo Marzorati; Barbara Vanhoecke; Tine De Ryck; Mehdi Sadaghian Sadabad; Iris Pinheiro; Sam Possemiers; Pieter Van den Abbeele; Lara Derycke; Marc Bracke; Jan Pieters; Tom Hennebel; Hermie J Harmsen; Willy Verstraete; Tom Van de Wiele Journal: BMC Microbiol Date: 2014-05-22 Impact factor: 3.605